A Novel Management to Severe Hypoattenuation Leaflet Thickening Following Transcatheter Aortic Valve Replacement
•First reported tissue plasminogen activator use to treat hypoattenuated leaflet thickening (HALT) post-transcatheter aortic valve replacement unresponsive to standard therapy.•Low-dose thrombolysis over 48 hours restored valve function.•Complete HALT resolution confirmed on computed tomography angiography after thrombolysis.
Authors
- Amr Essa (ORCID: https://orcid.org/0000-0003-1310-643X)
- Musa Sharkawi (ORCID: https://orcid.org/0000-0003-2200-0207)
- Dania Al Jabri
- Himax Patel (ORCID: https://orcid.org/0000-0001-9171-9456)
- Kimberly Atianzar (ORCID: https://orcid.org/0000-0003-4844-4383)
- Robert P. Summers (ORCID: https://orcid.org/0000-0001-8953-8007)
- John A. Lester (ORCID: https://orcid.org/0009-0000-6080-0016)
- Jarren Ypil
Institutions
- University of Georgia (US)
- University of Colorado Boulder (US)
- Augusta University (US)
- University of Colorado System (US)
Publication Details
- Journal
- Structural Heart
- Published
- 2025-07-26
- DOI
- https://doi.org/10.1016/j.shj.2025.100706
- Citations
- 1
- Primary Topic
- Venous Thromboembolism Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.87